# Phase 1 Clinical Study to Describe Biological Safety and Pharmacokinetics of Tyrphostin

> **NCT05487781** · EARLY_PHASE1 · UNKNOWN · sponsor: **Molecule X LLC** · enrollment: 48 (estimated)

## Conditions studied

- Healthy

## Interventions

- **COMBINATION_PRODUCT:** Tirfostina/L-Carnitina

## Key facts

- **NCT ID:** NCT05487781
- **Lead sponsor:** Molecule X LLC
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-24
- **Primary completion:** 2022-06-28
- **Final completion:** 2022-07-29
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2022-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05487781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05487781, "Phase 1 Clinical Study to Describe Biological Safety and Pharmacokinetics of Tyrphostin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05487781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*